Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Busy address KBO
12 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
Euthérapie Benelux from Anderlecht, company number BE0413600278, closed financial year 2025 with a result of € 57,526 after tax. For that financial year Euthérapie Benelux recorded a gross margin of € 4.7 million and equity of € 349,388. Compared with financial year 2024, the result moved from € 68,456 to € 57,526. The company is profitable. The company holds a healthy buffer. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on March 10, 2026.
€ 349,388
▼ 36% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 57,526
▼ 16% vs 2024
Profit after tax over the fiscal year.
€ 250,000 paid out
More than the year’s profit went to the shareholders; reserves fell.
People and assets in 2025
34.7
▼ 0.8 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 4.5 million
▼ 5% vs 2024
€ 129,300 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 126,626
▼ 33% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 1 million
▲ 9% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | - | € 4,427,651 | € 3,530,174 | - | |
| Gross margin | € 4,550,526 | € 4,809,656 | € 5,340,696 | € 4,694,421 | ▼ 12% |
| Profit after taxes | € 93,530 | € 120,936 | € 68,456 | € 57,526 | ▼ 16% |
| Equity | € 852,469 | € 973,405 | € 541,861 | € 349,388 | ▼ 36% |
| Total debts | € 1,237,476 | € 1,071,052 | € 1,654,108 | € 1,425,084 | ▼ 14% |
| Retained profit | € 581,469 | € 702,405 | € 270,861 | € 78,388 | ▼ 71% |
| Dividend | € 0 | € 0 | € 500,000 | € 250,000 | ▼ 50% |
| Balance sheet total | € 2,089,945 | € 2,044,457 | € 2,195,969 | € 1,774,471 | ▼ 19% |
| Employees (FTE) | 34.9 | 34.8 | 35.5 | 34.7 | ▼ 0.8 |
Key figures of Euthérapie Benelux, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 30 April 2027.
What happened to Euthérapie Benelux?
What happened at Euthérapie Benelux in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 57,526 (▼ 16% vs 2024). Source: NBB ↗
- Ziad Matta stepped down as director. NBB
- Philippe Gonnard stepped down as director. NBB
- François Vilette stepped down as director. NBB
- Ziad Matta became a director. NBB
- Philippe Gonnard became a director. NBB
- François Vilette became a director. NBB
- New establishment in Anderlecht. KBO
In short
From € 93,530 profit in 2022 to € 57,526 profit in 2025.
Paid € 603,592 in corporate taxes since 2022.
Best year ever: 2023, with € 120,936 profit.
On average € 135,300 of value added per employee in 2025.
A new publication or filing at Euthérapie Benelux? We notify you, reason included.
Follow Euthérapie BeneluxDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The shares are held by Biofarma (99.3%) and Les Laboratoires Servier (0.7%). It owns 0.1% of Daxispharma itself.
Directors
According to the 2025 annual accounts
since 2025 · until 2026
since 2025 · until 2026
since 2025 · until 2026
Shareholders
Biofarma
99.3%
Les Laboratoires Servier
0.7%
Participations
0.1%
Establishments
Establishment units
Physical locations of this company
Bergense Steenweg 1424
1070 Anderlecht
Internationalelaan 57
1070 Anderlecht
Active since 1 May 1974
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 12 companies are registered at this address.
All companies at this address →HILTI BELGIUM
€ 99.8 million revenue · 2024
Servier Benelux same network
€ 89.1 million revenue · 2025
MANUTAN
€ 59.3 million revenue · 2025
DAXISPHARMA same network
€ 7.1 million gross margin · 2025
COCA-COLA EUROPACIFIC PARTNERS BELGIUM
€ 1.6 billion revenue · 2025
+7 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0413.600.278
- VAT number
- BE 0413.600.278
- Registered office
- Bergense Steenweg 1424, 1070 Anderlecht
- Names & denominations
- Euthérapie Benelux
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 1 April 1974
- Peppol
- Active · Active since 16 Jan 2026
- Activities · NACE
Groothandel in farmaceutische en medische artikelen
Groothandel in farmaceutische producten